ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
Anders Sundin, Bertram Wiedenmann(Charité - Universitätsmedizin Berlin), Barbro Eriksson, Francesco Giammarile(International Atomic Energy Agency), Jarosław B. Ćwikła, Nicola Fazio(European Institute of Oncology), Andrea Rockall(Imperial College Healthcare NHS Trust), Dermot O’Toole(Trinity College Dublin), Andreas Kjær(University of Copenhagen), Catherine Lombard‐Bohas(Hospices Civils de Lyon), Stefano Fanti(Azienda USL di Bologna), Rodney J. Hicks(Flinders Medical Centre), Éric Baudin(Institut Gustave Roussy), Juan W. Valle(Cancer Research UK Manchester Institute), Marie‐Pierre Vullierme, Dik J. Kwekkeboom(Erasmus MC), Eric P. Krenning(Cyclotron (Netherlands)), Juan Manuel O’Connor(Instituto Alexander Fleming), Rudolf Arnold(Philipps University of Marburg)
Cited by 495
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k